Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.

Waskyra, developed by Fondazione Telethon, is the first gene therapy that the FDA has approved from a non-profit applicant.

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

A new analysis presented at ASH found Black AML patients were five years younger, on average, than White patients, and less ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Researchers at ASH shared Phase III data comparing the pre- and five-year posttreatment adjusted annualized bleeding rates, ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Researchers explored this question at ASH and shared data suggesting genomic instability in tumors with high TMB likely ...

Writing in JAMA, regulators said randomized controlled trials with a survival or time-to-event endpoint would be expected for approval of a new CAR T-cell therapy.